Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Heather L Gelhorn, Beatrice Osumili, Katelyn Brown, Melissa M Ross, Andrea Schulz, Gabriela Fernandez & Kristina S Boye. (2023) The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes. Patient Preference and Adherence 17, pages 793-805.
Read now
Read now
Bidur Banjara, Nabin Poudel, Kimberly B Garza, Salisa Westrick, Heather P Whitley, David Redden & Surachat Ngorsuraches. (2022) Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Patient Preference and Adherence 16, pages 3415-3428.
Read now
Read now
Heather L Gelhorn, Kristina S Boye, Huda Shalhoub, Louis S Matza, Jessica B Jordan, Ali Alhammad, Savita B Anand, Aishah A Ekhzaimy & Alena Strizek. (2020) Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia. Patient Preference and Adherence 14, pages 2231-2242.
Read now
Read now
Vivian T Thieu, Susan Robinson, Tessa Kennedy-Martin, Kristina S Boye & Luis-Emilio Garcia-Perez. (2019) Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes. Patient Preference and Adherence 13, pages 561-576.
Read now
Read now
Louis S. Matza, Kristina S. Boye, Brooke M. Currie, Rosirene Paczkowski, Laura F. Lando, Reema Mody & Jessica Jordan. (2018) Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. Current Medical Research and Opinion 34:8, pages 1457-1464.
Read now
Read now
Toshinari Asakura, Shuichi Suzuki, Toshihiko Aranishi & Zhihong Cai. (2018) Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch® among self-injection-naïve patients with type 2 diabetes mellitus in Japan. Current Medical Research and Opinion 34:6, pages 1117-1124.
Read now
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
Articles from other publishers (19)
Jaein Seo, Sebastian Heidenreich, Esraa Aldalooj, Jiat Ling Poon, Erik Spaepen, Elizabeth L. Eby & Rachel S. Newson. (2022) Patients’ Preferences for Connected Insulin Pens: A Discrete Choice Experiment Among Patients with Type 1 and Type 2 Diabetes. The Patient - Patient-Centered Outcomes Research 16:2, pages 127-138.
Crossref
Crossref
Bruno Guerci, Francesco Giorgino, Hélène Sapin, Kristina Boye, Jérémie Lebrec, Marco Orsini Federici, Elke Heitmann, Anne Dib, Martin Füchtenbusch & Luis‐Emilio García‐Pérez. (2022)
The
Real‐World
Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (
TROPHIES
): Patient disposition, clinical characteristics and treatment persistence at 12 months
. Diabetes, Obesity and Metabolism 24:12, pages 2373-2382.
Crossref
Crossref
Jay H. Shubrook, Michael Radin, Sarah N. Ali, Barrie Chubb, Kristina DiPietrantonio, Hannah Collings, Robin Wyn & Martina Smith. (2022) Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment. Advances in Therapy 39:9, pages 4114-4130.
Crossref
Crossref
Ayman A. Al Hayek & Mohamed A. Al Dawish. (2022) Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study. Advances in Therapy 39:4, pages 1582-1595.
Crossref
Crossref
Erin R. Weeda, Alyssa K. Muraoka, Matthew D. Brock & Jessica M. Cannon. (2021) Medication adherence to injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta‐analysis. International Journal of Clinical Practice 75:9.
Crossref
Crossref
José Gerardo González-González, Alejandro Díaz González-Colmenero, Juan Manuel Millán-Alanís, Lyubov Lytvyn, Ricardo Cesar Solis, Reem A Mustafa, Suetonia C Palmer, Sheyu Li, Qiukui Hao, Neri Alejandro Alvarez-Villalobos, Per Olav Vandvik & René Rodríguez-Gutiérrez. (2021) Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review. BMJ Open 11:7, pages e049130.
Crossref
Crossref
Ataru Igarashi, Brian Bekker Hansen, Jakob Langer, Francesca Tavella, Hannah Collings, Neil Davies & Robin Wyn. (2020) Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment. Advances in Therapy 38:1, pages 721-738.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas & Luis‐Emilio García‐Pérez. (2019) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism 22:3, pages 355-364.
Crossref
Crossref
Kentaro Okazaki, Tomotaka Shingaki, Zhihong Cai, Magaly Perez-Nieves & Lawrence Fisher. (2019) Successful Healthcare Provider Strategies to Overcome Psychological Insulin Resistance in Japanese Patients with Type 2 Diabetes. Diabetes Therapy 10:5, pages 1823-1834.
Crossref
Crossref
Victoria Divino, Kristina S. Boye, Jeremie Lebrec, Mitch DeKoven & Kirsi Norrbacka. (2019) GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. Diabetes Therapy 10:3, pages 1067-1088.
Crossref
Crossref
Takahiro Takase, Akinobu Nakamura, Chiho Yamamoto, Hiroshi Nomoto, Aika Miya, Midori Dannoura, Kyu Yong Cho, Yoshio Kurihara, Naoki Manda, Shin Aoki, Tatsuya Atsumi & Hideaki Miyoshi. (2018) Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation 10:3, pages 699-705.
Crossref
Crossref
Anne Brooks, Jakob Langer, Tommi Tervonen, Mads Peter Hemmingsen, Kosei Eguchi & Elizabeth Dansie Bacci. (2019) Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment. Diabetes Therapy 10:2, pages 735-749.
Crossref
Crossref
Simon Fifer, John Rose, Kim K. Hamrosi & Dan Swain. (2018) Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Services Research 18:1.
Crossref
Crossref
Anna Y. Zhou & Jennifer M. Trujillo. (2018) Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices. Diabetes Spectrum 31:4, pages 359-366.
Crossref
Crossref
Hitoshi Ishii, Hiroki Shin, Takahiro Tosaki, Tatsuya Haga, Yoshiki Nakajima, Toshihiko Shiraiwa, Nobuaki Watanabe, Miyuki Koizumi, Hiroki Nakajima, Sadanori Okada, Tsuyoshi Mashitani, Takako Mohri & Yasuhiro Akai. (2018) Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ). Diabetes Therapy 9:3, pages 1001-1019.
Crossref
Crossref
Ana Marta de Matos, Maria Paula de Macedo & Amélia Pilar Rauter. (2018) Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential. Medicinal Research Reviews 38:1, pages 261-324.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. Diabetes Therapy 8:2, pages 335-353.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy 8:2, pages 321-334.
Crossref
Crossref
Yoshio Sumida, Yuya Seko & Masashi Yoneda. (2017) Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research 47:4, pages 266-280.
Crossref
Crossref